

HR 7035

Biologics Market Transparency Act of 2022

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Mar 9, 2022

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Mar 10, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/7035>

Sponsor

Name: Rep. Manning, Kathy E. [D-NC-6]

Party: Democratic • **State:** NC • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Hudson, Richard [R-NC-8]	R · NC		Mar 9, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 10, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 S 4348	Related bill	Jul 13, 2022: Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.
117 HR 7667	Related bill	Jun 9, 2022: Received in the Senate.
117 S 4302	Related bill	May 25, 2022: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709)

Summary (as of Mar 9, 2022)

Biologics Market Transparency Act of 2022

This bill requires biologics manufacturers to notify the Food and Drug Administration in advance of withdrawing a product from sale.

Actions Timeline

- **Mar 10, 2022:** Referred to the Subcommittee on Health.
- **Mar 9, 2022:** Introduced in House
- **Mar 9, 2022:** Referred to the House Committee on Energy and Commerce.